Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment group 1: Injection of HRS-9563 or placebo | Experimental |
| |
| Treatment group 2: Injection of HRS-9563 or placebo | Experimental |
| |
| Treatment group 3: Injection of HRS-9563 or placebo | Experimental |
| |
| Treatment group 4: Injection of HRS-9563 or placebo | Experimental |
| |
| Treatment group 5: Injection of HRS-9563 or placebo | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HRS-9563, placebo | Drug | A single subcutaneous injection of HRS-9563 injection or placebo was administered |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence and severity of any adverse events | Evaluation was performed up to Day169 |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum observed plasma concentration of HRS-9563 (Cmax) | Evaluation was performed up to Day3 | |
| Time to Cmax (Tmax) | Evaluation was performed up to Day3 | |
| Area under the concentration-time curve from 0 to the last measurable time point after HRS-9563 administration (AUC0-t) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yuhan Guo | Contact | +0518-81220121 | yuhan.guo.yg21@hengrui.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Zhejiang Provincial People's Hospital | Recruiting | Hangzhou | Zhejiang | 314408 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Evaluation was performed up to Day3 |
| Area under the concentration-time curve from time 0 to infinity after HRS-9563 administration (AUC0-inf) | Evaluation was performed up to Day3 |
| Terminal elimination half-life of HRS-9563 (t1/2 | Evaluation was performed up to Day3 |
| Apparent clearance of HRS-9563 (CL/F) | Evaluation was performed up to Day3 |
| Apparent volume of distribution during terminal elimination phase of HRS-9563 (Vz/F) | Evaluation was performed up to Day3 |
| Cumulative amount of drug excreted in urine (Ae,urine) | Evaluation was performed up to Day3 |
| Cumulative percentage of dose recovered in urine (Fe,urine) | Evaluation was performed up to Day3 |